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m.8989G>CThe archetypal NARP syndrome is almost exclusively associated with the m.8993T>C/G mutation in the sixth
subunit of the mitochondrial ATP synthase, whereas other mutations in theMT-ATP6 gene primarily associate
with Leigh syndrome or Leber's hereditary optic neuropathy (LHON). We report a novel mitochondrial point
mutation, m.8989G>C, in a patient presenting with neuropathy, ataxia and retinitis pigmentosa constituting
the classical NARP phenotype. This mutation alters the amino acid right next to canonical NARP mutation. We
suggest that classic NARP syndrome relates to a defined dysfunction of p.MT-ATP6.
© 2012 Elsevier B.V. All rights reserved.1. IntroductionMitochondrial disorders (MID) encompass a heterogeneous group
of multi organ diseases caused by mutations in both the nuclear and
mitochondrial genomes. Mutations in the mtDNA primarily impair
the oxidative phosphorylation processes of the mitochondrial respi-
ratory chain thereby reducing the ATP production. Tissues with high
energy demands i.e. cerebrum, optic nerve, retina, muscle, heart and
endocrine glands are consequently often affected in MID, however
virtually every tissue can be affected, and clinical phenotypes range
from mild late-onset muscle weakness to perinatal death (Taylor
and Turnbull, 2005).
mtDNA mutations can either be maternally inherited, both from
asymptomatic or clinically affectedmothers, or arise de novo in the pro-
band. A central feature of MID is the heterogeneity of the symptoms
with phenotypic overlap between defined syndromes. The same muta-
tion may present highly variable phenotypes both within and between
families. This variation is attributed to the concept of heteroplasmy,; LHON, Leber's hereditary
yopathy, lactic acidosis, and
ith ragged red fibers; MID,
; NARP, neuropathy, ataxia,
University Hospital Copenha-
nmark. Tel.: +45 3545 4066;
l rights reserved.combined with the specific mtDNA haplotype background (D'Aurelio
et al., 2010), where high mutation loads associate with more severe
phenotypes.
One of the first mitochondrial mutations was identified by Harding
and colleagues (Holt et al., 1990)who described a combination of neu-
ropathy, ataxia and retinitis pigmentosa in a family heteroplasmic for
the m.8993T>G mutation in the MT-ATP6 gene. This syndrome was
subsequently coined NARP after the primary clinical features, howev-
er patients with a high mutation load of m.8993T>G present with
Leigh syndrome(Tatuch et al., 1992); a lethal subacute necrotizing
encephalomyelopathy. Several mutations throughout MT-ATP6 have
been associated with Leigh syndrome, whereas only mt.8993T>G
and the related mt.8993T>C, associate with the classical NARP
phenotype. Two other mutations, m.8618insT and m.9185T>C have
been associated with a NARP-like phenotype(Childs et al., 2007;
Lopez-Gallardo et al., 2009), but the clinical spectrum appears to be
quite variable.
Here we describe a patient with a canonical NARP phenotype
heteroplasmic for a novel m.8989G>C mutation in MT-ATP6. This
mutation leads to a p.A155P substitution, located right next to the
traditional NARP mutation p.L156R, indicating that the archetypal
NARP phenotype is linked to a defined dysfunction of p.MT-ATP6.
2. Patient
A now fifty-three year old male patient with uneventful birth and
early development. At age six an ophthalmological examination
373M. Duno et al. / Gene 515 (2013) 372–375noted a congenital left unilateral iris coloboma and normal visual
acuity without glasses. He attended primary and secondary school
for 10 years followed by 18 month military duty without any health
symptoms or complaints. He had vocational training in a men's
wear shop. Later he was appointed in a warehouse security service
and in airport security. Retrospectively, problems in the dark were
noticed in his late twenties and subjective mild symptoms of un-
steady gait and poor balance were encountered from the early forties.
Additionally, a bilateral sensorineural hearing loss for low frequencies
(2000–8000 Hz) has progressed during the last decade. The individu-
al symptoms presented initially were vague with very slow progres-
sion thus a common etiology was not previously suspected.
Due to gradually blurred vision an ophthalmological examination
was performed at age 45 and a diagnosis retinitis pigmentosa (RP)
was made. Fundus examination showed a typical late-stage RP with
severely constricted retinal vessels, diffuse retinal pigment epitheli-
um atrophy and a few irregular pigment aggregations peripherally.
Dark adaptation revealed an absent rod phase and the full-field elec-
troretinogram (ffERG) response was extinct. In addition a mild sub-
capsular cataract was present. At present he has concentric visual
field reduction and almost total loss of vision in the right eye, but is
still able to read large print with the left eye. At age fifty-two the
patient was referred for neurological assessment due to progressive
unsteadiness and tendency of falls when walking. The neurological
examination revealed a slight dysarthria, moderate gait ataxia, and
brisk patellar reflexes. Romberg's test was negative. MRI showed
moderate cerebellar atrophy but no other focal changes. Cognitive
functions are normal. There was no family history of any neurological
or ophthalmic disorders. Plasma lactate and creatine kinase levels
were normal. Neurophysiological examination showed severe senso-
ry neurogen affection with axonal loss in the lower extremities. In
the upper extremities there was a minor degree of sensory neurogen
loss. There was pronounced motor nerve affection with a reduced
response from posterior tibial nerve and with no signal from the left
deep peroneal nerve.
Histological examination of a biopsy from the musculus vastus
lateralis showed the majority of muscle fibers with normal polygonal
form and diameter with scattered pattern of single hypertrophic
fibers and a minor proportion of small atrophic angular fibers with a
vague sporadic CD56 positive staining. There was some minor fat
infiltration and type-grouping consistent with a chronic process of
de- and re-innervation. No ragged red fibers (RRF) or other morpho-
logical signs of mitochondrial myopathy were observed. Electron
microscopy showed normal number and form of the mitochondria.
3. Genetic and metabolic analysis
PCR and direct analysis for the three common mtDNA mutation
m.3243A>G (MELAS), m.8344A>G (MERRF) and c.8993T>G/C
(NARP) showed normal sequences but revealed heteroplasmic pres-
ence of a novel mutation m.8989G>C in mtDNA isolated from
blood. This mutation predicts a substitution of alanine at position
155 to proline (p.A155P) in the MT-ATP6. Subsequent analysis de-
tected the mutation in DNA isolated from muscle tissue, urine sedi-
ment and buccal mucosa from the proband (Fig. 1). The mutation
loads in the different tissues were estimated using the quantification
algorithm of the Mutation Surveyor detection software. The 80 year
old mother of the proband was examined clinically, and she
presented no obvious signs of NARP or NARP-related disorder. DNA
was isolated from a standard blood sample from the mother, and
assessed for the c.8989G>C mutation, which was not detected
(Fig. 1). The proband has a healthy elder sister who declined to be in-
vestigated genetically. There was no medical history of mitochondria
related symptoms.
Measurement of complex V (F1-ATPase) and complex II activity
in a mitochondria-enriched fraction from muscle tissue showed adecreased complex V/II activity ratio (1.0; control range: 1.5–3.4,
n=18) equivalent to 38% of the control median and 67% of the lowest
control value. The finding of decreased complex V activity, which is
similar in magnitude to that found in 11 patients with c.8993T>G/C
mutations (32–78% of the lowest control value; (Morava et al.,
2006)), supports a pathogenic effect of the c.8989G>C mutation.
4. Discussion
The identification of a heteroplasmic de novo c.8989G>Cmutation
in a patient with classic NARP syndrome has several implications. The
classic NARP phenotype has traditionally only been associated with
the m.8993T>C/G mutations where m.8993T>C, leading to p.L156P,
has a milder phenotypic expression than the original and more com-
mon m.8993T>G resulting in a p.L156R substitution(Rantamaki et al.,
2005; Santorelli et al., 1997). m.8993T>C is tolerated at a higher
heteroplasmic level than m.8993T>G, and symptomatic individuals
show mutation levels of >90% (Debray et al., 2007; Thorburn and
Rahman, 2011). These differences have been attributed to diversities
in the haplotype background, and assembly of the ATP-synthase
complex with the mitochondrial membrane (Kara et al., in press;
Vazquez-Memije et al., 2009). The novel m.8989G>C mutation alters
the highly conserved alanine residue to proline at position 155
(p.A155P) right next to p.L156. The clinical expression, the high
level of heteroplasmy and the introduction of an abnormal proline
residue all resembles the m.8993T>C mutation. Thus, the NARP phe-
notype might relate to a fairly specific alteration of the MT-ATP6 pro-
tein. Approx. 1% of Japanese are homoplasmic for the neutral
polymorphism m.8989G>A resulting in p.A155T, underscoring the
specific effect of the p.A155P substitution (www.LOVD.org). It has
been suggested that the NARP phenotype can be caused by loss-
of-function mutations in MT-ATP6, however, the index patient
heteroplasmic for the truncating MT-ATP6 mutation m.8618insT,
p.Thr33Hisfs*32 (Lopez-Gallardo et al., 2009), presented with devel-
opmental delay at age four and developed a severe phenotype by
the age of 12, which are atypical features for classic NARP. The two
closest located mutations, m.8950G>A and m.9035T>C only partly
associates with the NARP phenotype giving rise to LHON combined
with dystonia and progressive ataxia, respectively (Abu-Amero and
Bosley, 2005; Sikorska et al., 2009), further emphasizing the specific-
ity of NARP mutations.
The heteroplasmic level of c.8993T>G/C is believed to be fairly
similar in different tissues from the same individual, although tissue
variation can occur (Enns et al., 2006; White et al., 1999). Our patient
shows a clinically significant mutation level in DNA isolated from
muscle, buccal mucosa and urine sediment, whereas the mutation
level in mDNA isolated from blood, was considerably lower. Whether
this is due to an age dependent drift towards wild type in the hema-
topoietic linage, or reflects a stable distribution is unknown. The high
mutation level in muscle, buccal mucosa and urine sediment, sug-
gests that m.8989G>C arose very early in the embryonic develop-
ment, or was inherited. Although the mother of the proband did not
harbor the mutation in DNA isolated from blood, the possibility
exist that she could be heteroplasmic for m.8989G>C in other tissues,
and that the mutation has cleared from her hematopoietic cell line
due to age dependent drift. Such a progression has been observed
for other mDNA mutations (Rahman et al., 2001).
Neuropathy, ataxia and retinitis pigmentosa are all prevalentmulti
etiologic conditions, which can develop independently over several
years and thus escape being recognized as NARP. In the present case,
symptoms were slowly progressing with nearly two decades between
the initial symptoms of RP (night blindness) and the development of
ataxia. The confluent clinical presentation exposes the challenges of
recognizing NARP thereby potentially postponing or even missing
the diagnosis. The exact proportion of patients with a NARP pheno-
type being heteroplasmic for a mutation of m.8993T, is not exactly
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(Santorelli et al., 1997; Sikorska et al., 2009; Thorburn and Rahman,
2011). As the m.8993T>C/G mutation was one of the first pathogenic
mDNA mutation to be discovered, a wide range of methodologies
have been established to detect the specific mutation. Several of
these (e.g. RFLP, ARMS, TaqMan)will not necessarily detect a potential
c.8989G>T mutation. Thus, c.8989G>C might very well account for
more cases than the single patient described here. We therefore sug-
gest that patient referred for NARP should be assessed for c.8989G>C.
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